Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Neurology

• Publication date

  2006-04-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/01.wnl.0000204446.82823.28PMID 16606925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease

  2007cited by this paper
• Diffusion-weighted and perfusion MRI demonstrates parenchymal changes in complex partial status epilepticus.

  2005cited by this paper
• A prospective study of alcoholism and the risk of Parkinson’s disease

  2004cited by this paper
• Validity of the General Practice Research Database

  2003cited by this paper
• Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations

  2001cited by this paper
• Prospective study of caffeine consumption and risk of Parkinson's disease in men and women

  2001cited by this paper
• Relative Risk of Upper Gastrointestinal Complications among Users of Acetaminophen and Nonsteroidal Anti-Inflammatory Drugs

  2001cited by this paper
• Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide neuroprotection in the MPTP‐mouse model of Parkinson's disease

  2001cited by this paper
• Influence of strict, intermediate, and broad diagnostic criteria on the age‐ and sex‐specific incidence of Parkinson's disease

  2000cited by this paper
• Uncoupling of Blood Flow and Metabolism in Focal Epilepsy

  1998cited by this paper
• Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice

  1998cited by this paper
• Prophylactic aspirin and risk of peptic ulcer bleeding

  1995cited by this paper

• A Pathophysiological Model of Parkinson's Disease Based on Microvascular Flow Disturbance and Leukocyte-Mediated Oxidative Injury in Critical Pigmented Neuronal Niches.

  2026cites this paper
• Association between serum myeloperoxidase enzyme activity and Parkinson’s disease status

  2025cites this paper
• Rheumatoid arthritis drugs and the risk of Parkinson’s disease – a meta-analysis

  2025cites this paper
• The relation between Parkinson’s disease and non-steroidal anti-inflammatories; a systematic review and meta-analysis

  2024cites this paper
• Systemic inflammation and risk of Parkinson's disease: A prospective cohort study and genetic analysis.

  2024cites this paper
• Systemic lupus erythematosus is associated with increased risk of Parkinson’s disease

  2023cites this paper
• A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson’s disease: beneficial or detrimental effects

  2023cites this paper
• The complex role of inflammation and gliotransmitters in Parkinson's disease.

  2022cites this paper
• Protective effects of endotoxin tolerance on peripheral lipopolysaccharide-induced neuroinflammation and dopaminergic neuronal injury

  2022cites this paper
• Inflammation and immune dysfunction in Parkinson disease

  2022cites this paper
• Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson’s Disease

  2021cites this paper
• Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme

  2021cites this paper
• Novel Applications of NSAIDs: Insight and Future Perspectives in Cardiovascular, Neurodegenerative, Diabetes and Cancer Disease Therapy

  2021cites this paper
• Risk of Parkinson’s disease following gout: a population-based retrospective cohort study in Taiwan

  2020cites this paper
• Beta 2 agonists and the incidence of Parkinson's disease.

  2020cites this paper
• Risk of Parkinson disease Following Gout: A Population-Based Retrospective Cohort Study in Taiwan

  2020cites this paper
• Non-Steroidal Anti-Inflammatory Drugs and Parkinson’s Disease: A Systematic Review and Meta-analysis

  2020cites this paper
• If LRRK2 Set the Fire, Can Nonsteroidal Anti‐inflammatory Drugs Wet the Flames?

  2020influential citation
• Why do anti-inflammatory signals of bone marrow-derived stromal cells improve neurodegenerative conditions where anti-inflammatory drugs fail?

  2020cites this paper
• Gene-by-environment interactions in Alzheimer's disease and Parkinson's disease.

  2019cites this paper
• Pharmacological Targeting of Microglial Activation: New Therapeutic Approach

  2019cites this paper
• Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest?

  2019cites this paper
• Rosmarinic acid attenuates inflammatory responses through inhibiting HMGB1/TLR4/NF‐&kgr;B signaling pathway in a mouse model of Parkinson's disease

  2019cites this paper
• Risk of Multiple System Atrophy and the Use of Anti-Inflammatory Drugs: A Danish Register-Based Case-Control Study

  2019cites this paper
• Risk stratification and targeted neuroprotection in Parkinson disease utilising the glucocerebrosidase pathway

  2018cites this paper
• Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease

  2018cites this paper
• Short‐ and long‐term cost and utilization of health care resources in Parkinson's disease in the UK

  2018cites this paper
• Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease

  2018cites this paper
• Does a senescene-like phenotype in neurons contribute to brain ageing and neurodegeneration?

  2018cites this paper
• Prevalent cerebrovascular and cardiovascular disease in people with Parkinson’s disease: a meta-analysis

  2018cites this paper
• Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysis

  2018cites this paper
• An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition

  2017cites this paper
• Inflammation‐Mediated Neurodegeneration: Models, Mechanisms, and Therapeutic Interventions for Neurodegenerative Diseases

  2017cites this paper
• Non-Steroidal Anti-Inflammatory Drugs and Vitamin C in the Rotenone Induced Nigrostriatal Damage in Mice

  2017cites this paper
• Neuroinflammation as a Potential Mechanism Underlying Parkinsons Disease

  2017cites this paper
• Immunotherapies for Movement Disorders: Parkinson’s Disease and Amyotrophic Lateral Sclerosis

  2017cites this paper
• Neurodegenerative Disorders: Why Do We Need New Therapies?

  2017cites this paper
• Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype

  2017cites this paper
• Air pollution and Parkinson’s disease – evidence and future directions

  2017cites this paper
• Anti-inflammatory and neuroprotective activity of boswellic acids in rotenone parkinsonian rats.

  2017cites this paper
• The epidemiology of Parkinson's disease: risk factors and prevention.

  2016cites this paper
• Contributions of central and systemic inflammation to the pathophysiology of Parkinson ’ s disease

  2016cites this paper
• How can we address the controversies surrounding the use of NSAIDS in neurodegeneration?

  2016cites this paper
• The cannabinoid type-2 (CB2) receptor as a target for anti-inflammatory disease modification in Parkinson's disease

  2016cites this paper
• Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives

  2016cites this paper
• Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs.

  2015cites this paper
• Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair

  2015cites this paper
• Parkinson’s disease and enhanced inflammatory response

  2015cites this paper
• Clinical Aspects of Inflammation in Parkinson’s Disease

  2014cites this paper
• Attenuation of inflammatory-mediated neurotoxicity by Saururus chinensis extract in LPS-induced BV-2 microglia cells via regulation of NF-κB signaling and anti-oxidant properties

  2014cites this paper
• PET radioligands for in vivo visualization of neuroinflammation.

  2014cites this paper
• Clinical Aspects of Infl ammation in Parkinson's Disease

  2014cites this paper
• Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease.

  2013cites this paper
• EFEITO TIPO-ANTIDEPRESSIVO E ANTIOXIDANTE DO IBUPROFENO NO MODELO DA DOENÇA DE PARKINSON INDUZIDO POR ADMINISTRAÇÃO DE ROTENONA INTRAPERITONEAL EM RATOS

  2013influential citation
• Parkinson's disease: Evidence for environmental risk factors

  2013cites this paper
• Microglial Phenotype and Adaptation

  2013cites this paper
• Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease

  2013cites this paper
• Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship

  2013cites this paper
• Sodium salicylate protects against rotenone‐induced Parkinsonism in rats

  2013cites this paper
• Etude des mécanismes moléculaires impliqués dans l'infiltration cérébrale des lymphocytes T dans la maladie de Parkinson

  2012cites this paper
• Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.

  2012cites this paper
• Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated neuroprotection against 1-methyl-4-phenyl pyridinium-induced cytotoxicity.

  2012cites this paper
• Inflammation in Parkinson’s Disease: Causes and Consequences

  2012cites this paper
• Proton pump inhibitors and traditional nonsteroidal anti‐inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury

  2012cites this paper
• Inflammation in Parkinson's disease.

  2012cites this paper
• Role of the prolyl isomerase Pin1 in the pathogenesis of Parkinson's disease and neuroprotection by novel targeted compounds in pre-clinical animal models of the disease

  2012cites this paper
• The neuroprotective role of osteopontin in in-vitro and in-vivo models of Parkinson's disease

  2012cites this paper
• Dégénérescence neuronale et neuroinflammation : identification de nouveaux acteurs potentiels

  2012cites this paper
• Non-Steroidal Anti-Inflammatory Drug Use and the Risk of Parkinson’s Disease

  2011cites this paper
• Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies.

  2011cites this paper
• The Promise of Neuroprotective Agents in Parkinson’s Disease

  2011cites this paper
• Peripheral Inflammation Increases the Damage in Animal Models of Nigrostriatal Dopaminergic Neurodegeneration: Possible Implication in Parkinson's Disease Incidence

  2011cites this paper
• NSAID use and risk of Parkinson disease: a population‐based case‐control study

  2011cites this paper
• Use of ibuprofen and risk of Parkinson disease

  2011cites this paper
• Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study

  2011cites this paper
• Parkinson’s disease or Parkinson symptoms following seasonal influenza

  2011cites this paper
• Risk of incident depression in patients with Parkinson disease in the UK

  2011cites this paper
• Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway.

  2011cites this paper
• Epidemiology and etiology of Parkinson’s disease: a review of the evidence

  2011cites this paper
• Inflammation and gliosis in neurological diseases--clinical implications.

  2011cites this paper
• The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration

  2011cites this paper
• The effect of repetitive transcranial magnetic stimulation on a model rat of Parkinson's disease

  2010cites this paper
• Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells.

  2010cites this paper
• Risk for Parkinson's disease among patients with osteoarthritis: A Danish cohort study

  2010cites this paper
• Anti-inflammatory drugs and risk of Parkinson disease

  2010cites this paper
• Environmental Epidemiology of Sporadic Parkinsons Disease

  2010cites this paper
• Inflammatory Mechanisms of Neurodegeneration in Toxin-Based Models of Parkinson's Disease

  2010cites this paper
• Cyclooxygenase and Neuroinflammation in Parkinson’s Disease Neurodegeneration

  2010cites this paper
• Common Pathways to Neurodegeneration and Co-morbid Depression

  2010cites this paper
• Risk of stroke in patients with idiopathic Parkinson disease.

  2010cites this paper
• Advances in environmental epidemiology

  2010cites this paper
• Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.

  2010cites this paper
• Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation

  2010cites this paper
• Cancer risk in association with Parkinson disease: a population-based study.

  2010cites this paper
• Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease.

  2010cites this paper
• Environmental Factors and Parkinson's Disease

  2010cites this paper
• Neuroinflammation in Parkinson’s Disease

  2009cites this paper
• NSAIDs and cardiovascular drugs in neurodegenerative and cerebrovascular diseases

  2009cites this paper
• Use of antidepressants and the risk of Parkinson’s disease: a prospective study

  2009cites this paper
• 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Does Not Elicit Long-Lasting Increases in Cyclooxygenase-2 Expression in Dopaminergic Neurons of Monkeys

  2009cites this paper